MiniMed Group (MMED) news centers on diabetes technology, insulin delivery systems, CGM integrations, automated insulin delivery algorithms, and the company's development as a newly public Nasdaq-listed medical device business. MiniMed describes itself as a global leader in insulin delivery, with therapies supporting people with diabetes in more than 80 countries.
MMED headlines often matter because the company operates in a regulated care category where product access, sensor compatibility, clinical evidence, reimbursement availability, and regulatory clearances can affect adoption. Company announcements have covered U.S. and European product launches, MiniMed Flex™ availability, Instinct sensors made by Abbott, SmartGuard™ technology, Medicare and Medicare Advantage access, FDA-related activity, CE Mark activity, and pivotal trial updates.
Investors following MiniMed news also watch earnings releases, investor conference participation, board updates, separation-related developments, Medtronic ownership context, and SEC-filed material event reports. Because MiniMed's ecosystem combines pumps, sensors, algorithms, apps, and service, product news can touch several parts of the diabetes management experience at once.
Frequent review of MMED news can help track how MiniMed communicates product availability, regulatory progress, clinical evidence, financial results, and governance changes as an independent public company in diabetes technology.
MiniMed (Nasdaq: MMED) reported strong Q4 and fiscal 2026 results and issued fiscal 2027 guidance.
Q4 net sales were $837 million, up 15.6% reported and 8.7% organic. Fiscal 2026 net sales reached a record $3.102 billion, up 14.2% reported and 8.0% organic, led by international growth and higher CGM attachment.
Fiscal 2027 guidance calls for ~10% organic revenue growth (including 1.0–1.5% from an extra week) and ~16% adjusted EBITDA margin. MiniMed advanced its pipeline with FDA clearances for MiniMed Flex and MiniMed Go, CE Marks for expanded MiniMed 780G indications, new launches, and an extended Abbott sensor partnership.
MiniMed (Nasdaq: MMED) will showcase its new MiniMed Flex™ pump and recently launched MiniMed Go™ smart insulin pen at the American Diabetes Association Scientific Sessions in New Orleans, June 5-8, 2026.
MiniMed will offer hands-on demos, sponsored symposia, and multiple poster presentations on MiniMed™ 780G and Instinct™ sensor real-world and clinical outcomes.
MiniMed (Nasdaq: MMED) announced that its management will join a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference.
The session is scheduled for Monday, June 8, 2026, at 11:20 a.m. EDT, with a live webcast and replay available on the MiniMed investor relations website.
MiniMed (Nasdaq: MMED) reported a randomized crossover trial showing virtually identical glycemic outcomes using the MiniMed 780G system with either Simplera Sync or Abbott’s Instinct sensor in 24 adults with type 1 diabetes.
Time in Range was about 80%, HbA1c about 6.7–6.8%, with no DKA or severe hypoglycemia. Real-world data from over 20,000 U.S. users also showed strong glycemic control across Guardian 4 and Instinct sensors, supporting the central role of the SmartGuard algorithm.
MiniMed (Nasdaq: MMED) will report fourth quarter and full fiscal year 2026 results on Wednesday, June 3, 2026. A news release will be issued at ~3:45 a.m. PDT and a webcast will follow at 5:45 a.m. PDT.
According to MiniMed, the fiscal year ends on April 24, 2026, and a replay and transcript will be posted within 24 hours at the company investor site.
MiniMed (Nasdaq: MMED) announced FDA clearance of MiniMed Flex™ on March 18, 2026, a screenless, smartphone‑controlled insulin pump about half the size of the 780G with a 300‑unit reservoir. The pump uses SmartGuard™ with Meal Detection™ and demonstrated 80% Time in Range in real‑world results.
Commercial launch will pair Flex with Simplera Sync™ and Abbott Instinct sensors, begin a select customer phase this spring, and expand broadly in summer. Eligible 780G users can upgrade via the MiniMed™ Forward Program for $0.
MiniMed (Nasdaq: MMED) closed its initial public offering, selling 28,000,000 shares at $20.00 per share and began Nasdaq trading on March 6, 2026. Net proceeds to MiniMed were approximately $538 million after underwriting discounts and expenses.
As of closing, Medtronic owns ~90.03% of MiniMed common stock. MiniMed intends to use part of the proceeds for general corporate purposes and used the remainder to repay intercompany debt owed to Medtronic.
MiniMed (Nasdaq: MMED) began trading on the Nasdaq Global Select Market on March 6, 2026 following its initial public offering. Leadership, including CEO Que Dallara, rang the Nasdaq Opening Bell to mark the listing. A Form S-1 registration statement has been filed and declared effective by the SEC.
The company positions itself as a global diabetes management leader and the only provider of a fully integrated insulin delivery system with connected devices designed to work together.
MiniMed Group (Nasdaq: MMED) began trading March 6, 2026 on the Nasdaq Global Select Market following an oversubscribed IPO.
The offering was described as the second largest IPO in medtech history and positions MiniMed to operate as a standalone company, while supporting Medtronic (NYSE: MDT)'s capital-focus strategy amid geopolitical market uncertainty.
MiniMed Group (proposed Nasdaq: MMED) launched its IPO roadshow on Feb 24, 2026, offering 28,000,000 shares with an expected price range of $25.00–$28.00 per share and a 30-day over-allotment option for 4,200,000 shares.
Upon completion Medtronic (NYSE: MDT) would retain approximately 90.03% ownership (or 88.70% if the over-allotment is exercised). Proceeds will fund general corporate purposes, repay intercompany debt, and provide additional consideration to Medtronic. A Form S-1 has been filed but is not yet effective.